Form 8.3 - Horizon Therapeutics PLC
Source: RNS
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
|
1. |
KEY INFORMATION |
||||||
|
|
|||||||
|
Name of person dealing |
The Capital Group Companies, Inc. |
||||||
|
Company dealt in |
Horizon Therapeutics PLC |
||||||
|
Class of relevant security to which the dealings being disclosed relate |
US$0.0001 ordinary shares (IE00BQPVQZ61) |
||||||
|
Date of dealing |
05 December 2022 |
||||||
|
|
|||||||
|
2. |
INTERESTS AND SHORT POSITIONS |
||||||
|
|
|||||||
|
(a) |
Interests and short positions (following dealing) in the class of relevant security dealt in |
||||||
|
|
|||||||
|
|
Long |
Short |
|||||
|
|
Number |
(%) |
Number |
(%) |
|||
|
(1) |
Relevant securities |
10,076,263 shares |
4.45 % |
|
|
||
|
(2) |
Derivatives (other than options): |
|
|
|
|
||
|
(3) |
Options and agreements to purchase/sell: |
|
|
|
|
||
|
|
Total |
10,076,263 shares |
4.45 % |
|
|
||
|
|
|||||||
|
(b) |
Interests and short positions in relevant securities of the company, other than the class dealt in |
||||||
|
|
|||||||
|
|
|||||||
|
Class of relevant security: |
Long |
Short |
|||||
|
|
Number |
(%) |
Number |
(%) |
|||
|
(1) |
Relevant securities |
|
|
|
|
||
|
(2) |
Derivatives (other than options): |
|
|
|
|
||
|
(3) |
Options and agreements to purchase/sell: |
|
|
|
|
||
|
|
Total |
|
|
|
|
||
|
3. |
DEALINGS |
|
||||||||||
|
|
|
|||||||||||
|
(a) |
Purchases and sales |
|
||||||||||
|
|
|
|||||||||||
|
Purchase/sale |
Number of relevant securities |
Price per unit |
|
|||||||||
|
Purchase |
448 shares |
98.4800 - USD |
|
|||||||||
|
Purchase |
118 shares |
104.8500 - USD |
|
|||||||||
|
Purchase |
76 shares |
98.8150 - USD |
|
|||||||||
|
Purchase |
47 shares |
99.0151 - USD |
|
|||||||||
|
Purchase |
23 shares |
99.0347 - USD |
|
|||||||||
|
Sale |
9,999 shares |
100.1861 - USD |
|
|||||||||
|
|
|
|||||||||||
|
(b) |
Derivatives transactions (other than options transactions) |
|
||||||||||
|
|
|
|||||||||||
|
Product name e.g. CFD |
Nature of transaction |
Number of relevant securities |
Price per unit |
|
||||||||
|
|
|
|
|
|
||||||||
|
|
|
|||||||||||
|
(c) |
Options transactions in respect of existing relevant securities |
|||||||||||
|
|
||||||||||||
|
(i) |
Writing, selling, purchasing or varying |
|||||||||||
|
|
||||||||||||
|
Product name e.g. call option |
Writing, purchasing, selling, varying etc. |
Number of securities to which the option relates |
Exercise price |
Type, e.g. American, European etc. |
Expiry date |
Option money paid/ received per unit |
||||||
|
|
|
|
|
|
|
|
||||||
|
|
|
|||||||||||
|
(ii) |
Exercising |
|
||||||||||
|
|
|
|||||||||||
|
Product name e.g. call option |
Number of securities |
Exercise price per unit |
|
|||||||||
|
|
|
|
|
|||||||||
|
|
|
|||||||||||
|
(d) |
Other dealings (including subscribing for new securities) |
|
||||||||||
|
|
|
|||||||||||
|
Nature of transaction |
Details |
Price per unit (if applicable) |
|
|||||||||
|
|
|
|
|
|||||||||
|
4. |
OTHER INFORMATION |
|
|
|
||
|
Agreements, arrangements or understandings relating to options or derivatives |
||
|
|
||
|
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. |
||
|
None |
||
|
|
||
|
Is a Supplemental Form 8 attached? |
NO |
|
|
|
||
|
Date of disclosure |
06 December 2022 |
|
|
Contact name |
Art Romero |
|
|
Telephone number |
213 452 2709 |
|
|
If a connected EFM, name of offeree/offeror with which connected |
|
|
|
If a connected EFM, state nature of connection |
|
|
|
|
||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
